Genetesis, a Cincinnati, OH-based medical device startup, closed a $1.2M seed financing.
The round was co-led by CincyTech and Mark Cuban’s Radical Investments, with participation from Loud Capital, Danmar Capital, Wilson Sonsini Investment Company, Genetesis management and private angels.
The company now employs a team of ten. The company will use the funds to scale its engineering, launch additional clinical studies and seek regulatory clearance from the FDA.
Founded in Mason, Ohio in 2013 by CEO Peeyush Shrivastava, Genetesis as developed the CardioFlux™ technology, a medical device that provides doctors with a non-invasive tool for seeing how the heart beats. CardioFlux™ gives physicians 3D mapping tools, to understand each patient’s underlying electrical activity, which can potentially be used to diagnose, characterize, and guide treatment for a variety of cardiac disorders including myocardial ischemia, atrial fibrillation, ventricular tachycardia and a variety of other cardiac arrhythmias.